查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1700176

2032 年急性缺血性脑中风诊断和治疗市场预测：按药物类型、诊断方法、疗法、最终用户和地区进行的全球分析

Acute Ischemic Stroke Diagnosis and Treatment Market Forecasts to 2032 - Global Analysis By Drug Type, Diagnosis Method, Treatment, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球急性缺血性脑中风(AIS) 诊断和治疗市场预计在 2025 年达到 64 亿美元，到 2032 年将达到 111 亿美元，预测期内的复合年增长率为 8.1%。

急性急性缺血性脑中风（AIS）是由动脉阻塞引起的严重脑血管事件，导致脑血流减少和潜在的神经元损伤。基于人工智慧的中风诊断和新型血栓移除设备等新兴趋势正在塑造市场动态，并推动神经血管领域的製药和医疗设备公司之间的竞争。

根据国际糖尿病联盟的最新资料，2021年全球约有5.37亿20至79岁人群患有糖尿病，预计到2030年这一数字将增至6.43亿，到2045年将增至7.83亿。

中风发生率增加

全球范围内急性缺血性脑中风（AIS）盛行率的上升是市场发展的关键驱动因素。人口老化和心血管疾病负担加重导致中风发生率上升。此外，久坐不动的生活方式、不良饮食和吸烟等生活方式因素进一步加剧了中风的风险。政府和医疗保健组织也在加强宣传宣传活动，以促进早期发现和早期疗育。中风患者的急剧增加正在推动AIS诊断和治疗市场的成长。

治疗选择有限

AIS 市场的主要限制因素之一是有效治疗的治疗窗口有限。中风治疗的时间敏感度限制了某些治疗方法（如溶栓和血栓切除术）的应用。诊断延迟或患者到医疗机构就诊延迟往往会导致错过最佳治疗机会。这些挑战凸显了改善医疗基础设施和加快诊断通讯协定的必要性。治疗时间有限是市场扩张的重大障碍。

人工智慧与远端医疗的融合

人工智慧（AI）与远端医疗的融合为AIS市场创造了巨大的机会。人工智慧诊断工具可以提高中风检测的准确性和速度，从而实现及时干预。远端医疗促进了远距会诊，使专家能够在服务不足的地区做出即时治疗决策。此外，人工智慧预测分析可以帮助识别高风险个体并采取预防措施。预计对数位健康解决方案的投资增加将推动该领域的创新和成长。

治疗相关併发症的风险

可能出现的治疗相关併发症对 AIS 市场构成威胁。血栓溶解疗法和机械血栓切除术等治疗方法具有出血、感染和血管损伤等风险。此外，先进治疗方法的高成本及其相关风险可能会限制其在资源受限的环境中的应用。确保患者安全同时保持治疗效果仍是一项重大挑战。透过改进通讯协定和更安全的治疗方案解决这些问题对于市场成长至关重要。

COVID-19的影响：

COVID-19 疫情对 AIS 诊断和治疗市场产生了各种影响。一方面，疫情期间对医疗基础设施的关注和快速诊断的需求加速了先进技术的采用。然而，这次疫情凸显了远端医疗和远端监控的重要性，预计它们将在疫情后的中风管理中发挥更大的作用。

抗血小板药物市场预计将在预测期内占据最大份额

抗血小板药物因其在预防血栓形成方面的有效性，预计将在预测期内占据最大的市场占有率。这些药物对于治疗急性缺血性脑中风至关重要，并可降低復发风险。抗血小板药物因其在预防中风方面的有效性而被广泛应用于临床实践中。药物配方和给药方法的进步提高了患者的依从性和治疗效果。此外，中风发病率的上升、对预防医学的日益重视以及持续的研究和开发预计将导致更有效的抗血小板疗法的推出，并加强其在市场上的地位。

预计成像技术领域在预测期内将实现最高的复合年增长率。

由于电脑断层扫描和 MRI 等影像技术的进步提高了诊断的准确性和速度，预计影像技术领域将在预测期内见证最高成长率。对早期和准确的中风检测的需求推动了对先进诊断成像解决方案的需求不断增长。预计医疗保健基础设施投资的增加（尤其是在发展中地区）将推动影像技术的采用。此外，诊断成像模式的持续进步将提高其能力，从而带来更好的患者治疗效果，而医疗保健提供者和技术公司之间的合作可能会加速尖端成像解决方案的采用。

占比最大的地区：

预计北美地区将在预测期内占据最大的市场占有率。人们对中风症状和及时干预的重要性的认识不断提高，推动了对先进诊断和治疗解决方案的需求。主要市场参与者的存在和对研发的持续投资进一步加强了该地区的市场地位。政府旨在改善中风治疗的措施促进了这一增长。此外，高血压和糖尿病等生活型态相关风险因素的盛行率上升也有望推动市场发展。

复合年增长率最高的地区：

在预测期内，由于医疗保健基础设施的快速发展和医疗保健支出的增加，预计亚太地区将呈现最高的复合年增长率。中国、印度和日本等国家处于领先地位，大力投资医疗技术和基础设施。人们对中风的认识不断提高以及早期诊断和治疗的重要性正在推动市场需求。政府的优惠政策和改善医疗保健的努力也促进了这一增长。中风盛行率的上升以及高血压和糖尿病等相关风险因素预计将进一步推动市场扩张。

提供免费客製化：

订阅此报告的客户将获得以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球急性缺血性脑中风诊断和治疗市场（按药物类型）

  • 纤溶药物
  • 抗血小板药物
  • 抗凝血剂
  • 神经保护剂
  • 其他药物类型

6. 全球急性缺血性脑中风诊断与治疗市场（依诊断方法）

  • 影像技术
    • 电脑断层扫描 (CT)
    • 磁振造影（MRI）
    • CT血管造影术
    • 磁振血管造影术
  • 血液检查
  • 心电图
  • 其他诊断方法

7. 全球急性缺血性脑中风诊断与治疗市场（依疗法）

  • 药物治疗
  • 外科手术和介入治疗
  • 其他治疗

8. 全球急性缺血性脑中风诊断和治疗市场（按最终用户）

  • 门诊手术中心
  • 诊断中心
  • 医院
  • 研究机构
  • 其他最终用户

9. 全球急性缺血性脑中风诊断与治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Abbott Laboratories
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Genentech, Inc. by Roche Group
  • Hitachi, Ltd.
  • Integral Diagnostics（IDX）Group
  • Koninklijke Philips NV
  • Mediso Kft.
  • Medtronic PLC
  • Memorial Health
Product Code: SMRC29079

According to Stratistics MRC, the Global Acute Ischemic Stroke Diagnosis and Treatment Market is accounted for $6.4 billion in 2025 and is expected to reach $11.1 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Acute Ischemic Stroke (AIS) is a critical cerebrovascular event caused by an arterial occlusion, leading to reduced cerebral blood flow and potential neuronal damage. Emerging trends such as AI-driven stroke diagnostics and novel clot-retrieval devices are shaping market dynamics, fostering competition among pharmaceutical and medical device companies in the neurovascular sector.

According to the International Diabetes Federation's recent data, approximately 537 million people aged 20-79 years were living with diabetes worldwide in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Rising stroke incidence

The increasing prevalence of acute ischemic stroke (AIS) globally is a significant driver for the market. Aging populations and the rising burden of cardiovascular diseases contribute to the growing incidence of stroke. Additionally, lifestyle factors such as sedentary habits, poor diet, and smoking further exacerbate the risk of stroke. Governments and healthcare organizations are also focusing on awareness campaigns to promote early detection and intervention. This surge in stroke cases is propelling the growth of the AIS diagnosis and treatment market.

Restraint:

Limited treatment window

One of the primary restraints in the AIS market is the narrow therapeutic window for effective treatment. The time-sensitive nature of stroke management limits the applicability of certain interventions, such as thrombolysis and thrombectomy. Delays in diagnosis or patient presentation to healthcare facilities often result in missed opportunities for optimal treatment. These challenges underscore the need for improved healthcare infrastructure and faster diagnostic protocols. The limited treatment window remains a critical barrier to market expansion.

Opportunity:

AI and telemedicine integration

The integration of artificial intelligence (AI) and telemedicine presents a significant opportunity for the AIS market. AI-powered diagnostic tools can enhance the accuracy and speed of stroke detection, enabling timely intervention. Telemedicine facilitates remote consultations, allowing specialists to guide treatment decisions in real-time, even in underserved regions. Furthermore, AI-driven predictive analytics can aid in identifying high-risk individuals, enabling preventive measures. The growing investment in digital health solutions is expected to drive innovation and growth in this segment.

Threat:

Risk of treatment-related complications

The potential for treatment-related complications poses a threat to the AIS market. Interventions such as thrombolytic therapy and mechanical thrombectomy carry risks of bleeding, infection, or vascular damage. Additionally, the high cost of advanced treatments and the associated risks may limit their adoption in resource-constrained settings. Ensuring patient safety while maintaining treatment efficacy remains a critical challenge. Addressing these concerns through improved protocols and safer therapeutic options is essential for market growth.

Covid-19 Impact:

The COVID-19 pandemic has had a mixed impact on the AIS diagnosis and treatment market. On one hand, the focus on healthcare infrastructure and the need for rapid diagnostics during the pandemic accelerated the adoption of advanced technologies. However, the pandemic highlighted the importance of telemedicine and remote monitoring, which are expected to play a larger role in post-pandemic stroke management.

The antiplatelet drugs segment is expected to be the largest during the forecast period

The Antiplatelet Drugs segment is expected to account for the largest market share during the forecast period due to their efficacy in preventing clot formation. These drugs are critical in the management of acute ischemic strokes, reducing the risk of recurrence. The widespread adoption of antiplatelet drugs in clinical practice is driven by their proven benefits in stroke prevention. Advances in drug formulations and delivery methods are enhancing patient compliance and outcomes. Moreover, segment's growth is further supported by the increasing incidence of stroke and the emphasis on preventive care and continuous research and development are expected to introduce more effective antiplatelet therapies, solidifying their market position.

The imaging techniques segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Imaging Techniques segment is predicted to witness the highest growth rate due to Innovations in imaging technology, such as CT scans and MRI, are improving diagnostic precision and speed. The growing demand for advanced imaging solutions is driven by the need for early and accurate stroke detection. Increased investment in healthcare infrastructure, particularly in developing regions, is expected to boost the adoption of imaging techniques. Additionally, continuous advancements in imaging modalities are enhancing their capabilities, leading to better patient outcomes and collaborations between healthcare providers and technology firms are likely to accelerate the adoption of cutting-edge imaging solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to Increasing awareness about stroke symptoms and the importance of timely intervention is driving the demand for advanced diagnostic and treatment solutions. The presence of key market players and continuous investment in R&D further bolster the region's market position. Government initiatives aimed at improving stroke care are contributing to the growth. The rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes, is also expected to fuel the market.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR due to rapidly developing healthcare infrastructure and increasing healthcare expenditure. Countries like China, India, and Japan are at the forefront, with significant investments in healthcare technology and infrastructure. The growing awareness about stroke and the importance of early diagnosis and treatment is boosting market demand. Favorable government policies and initiatives aimed at improving healthcare accessibility are also contributing to the growth. The increasing prevalence of stroke and related risk factors, such as hypertension and diabetes, is expected to further drive market expansion.

Key players in the market

Some of the key players in Acute ischemic stroke diagnosis and treatment market include Abbott Laboratories, BIOTRONIK SE & Co KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Canon Medical Systems Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare Technologies Inc., Genentech, Inc. by Roche Group, Hitachi, Ltd., Integral Diagnostics (IDX) Group, Koninklijke Philips N.V., Mediso Kft., Medtronic PLC and Memorial Health.

Key Developments:

In January 2025, Philips Healthcare planned to debut its Telestroke Connect Platform, a cloud-based telemedicine solution that links rural clinics with stroke specialists via augmented reality (AR). The platform will support live 3D imaging reviews and collaborative treatment planning, addressing gaps in access to specialized stroke care in underserved regions.

In March 2024, Siemens Healthineers launched the AI-Powered NeuroVision CT Suite, a next-generation imaging system designed to accelerate the detection of acute ischemic strokes. The suite integrates artificial intelligence to analyze brain scans in under 3 minutes, enabling rapid identification of blockages and guiding treatment decisions for thrombolysis or thrombectomy.

In February 2024, Medtronic introduced the Solitaire(TM) X Platinum+ Stent Retriever, an advanced thrombectomy device optimized for precision in removing blood clots. The device features enhanced flexibility and radial force, improving success rates in complex neurovascular anatomies while minimizing vessel trauma.

Drug Types Covered:

  • Thrombolytics
  • Antiplatelet Drugs
  • Anticoagulants
  • Neuroprotective Agents
  • Other Drug Types

Diagnosis Methods Covered:

  • Imaging Techniques
  • Blood Tests
  • Electrocardiogram
  • Other Diagnosis Methods

Treatments Covered:

  • Medication-Based Treatment
  • Surgical & Interventional Treatments
  • Other Treatments

End Users Covered:

  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Hospitals
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Thrombolytics
  • 5.3 Antiplatelet Drugs
  • 5.4 Anticoagulants
  • 5.5 Neuroprotective Agents
  • 5.6 Other Drug Types

6 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Diagnosis Method

  • 6.1 Introduction
  • 6.2 Imaging Techniques
    • 6.2.1 Computed Tomography (CT) Scan
    • 6.2.2 Magnetic Resonance Imaging (MRI)
    • 6.2.3 CT Angiography
    • 6.2.4 MR Angiography
  • 6.3 Blood Tests
  • 6.4 Electrocardiogram
  • 6.5 Other Diagnosis Methods

7 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Treatment

  • 7.1 Introduction
  • 7.2 Medication-Based Treatment
  • 7.3 Surgical & Interventional Treatments
  • 7.4 Other Treatments

8 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Diagnostic Centers
  • 8.4 Hospitals
  • 8.5 Research Institutes
  • 8.6 Other End Users

9 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 BIOTRONIK SE & Co KG
  • 11.3 Boehringer Ingelheim International GmbH
  • 11.4 Boston Scientific Corporation
  • 11.5 Canon Medical Systems Corporation
  • 11.6 F. Hoffmann-La Roche Ltd.
  • 11.7 Fujifilm Holdings Corporation
  • 11.8 GE Healthcare Technologies Inc.
  • 11.9 Genentech, Inc. by Roche Group
  • 11.10 Hitachi, Ltd.
  • 11.11 Integral Diagnostics (IDX) Group
  • 11.12 Koninklijke Philips N.V.
  • 11.13 Mediso Kft.
  • 11.14 Medtronic PLC
  • 11.15 Memorial Health

List of Tables

  • Table 1 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Thrombolytics (2024-2032) ($MN)
  • Table 4 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Antiplatelet Drugs (2024-2032) ($MN)
  • Table 5 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Anticoagulants (2024-2032) ($MN)
  • Table 6 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Neuroprotective Agents (2024-2032) ($MN)
  • Table 7 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 8 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 9 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Imaging Techniques (2024-2032) ($MN)
  • Table 10 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Computed Tomography (CT) Scan (2024-2032) ($MN)
  • Table 11 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) ($MN)
  • Table 12 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By CT Angiography (2024-2032) ($MN)
  • Table 13 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By MR Angiography (2024-2032) ($MN)
  • Table 14 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 15 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Electrocardiogram (2024-2032) ($MN)
  • Table 16 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Diagnosis Methods (2024-2032) ($MN)
  • Table 17 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 18 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Medication-Based Treatment (2024-2032) ($MN)
  • Table 19 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Surgical & Interventional Treatments (2024-2032) ($MN)
  • Table 20 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
  • Table 21 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By End Users (2024-2032) ($MN)
  • Table 22 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 24 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 25 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 26 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above. Wholesale Markets